BioVersys to present Phase 2 alpibectir-ethionamide data in tuberculosis patients
GSK•BioVersys and GSK will present Phase 2 alpibectir-ethionamide data at the Union World Conference on Lung Health in Rio de Janeiro on November 17-20, 2026.
1. Conference presentations
The presentations will cover early antibacterial activity and safety in patients with newly diagnosed drug-sensitive pulmonary tuberculosis. A Phase 2a presentation will detail alpibectir’s enhancement of ethionamide activity against clinical tuberculosis isolates.
